Raymond James conferma Strong Buy su Viking Therapeutic

AI Briefing

• – Raymond James upgrades Viking Therapeutic to Strong Buy, citing strong growth prospects for its lead compound.
• – The investment firm expects improved revenue and profitability in the coming years.
• – Viking Therapeutic's lead compound shows promise in treating rare genetic disorders.